Thousands of women will be given NHS access to two “life-changing” drugs used to treat breast cancer.
Palbociclib was initially rejected because of its high cost, the BBC reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
“One cycle of palbociclib - or 21 capsules - costs £2,950 for a pack of 21. For 63 tablets of ribociclib, the price is the same,” it says.
However, following price negotiations, 8,000 people in England will now have access to the medications.
Women with oestrogen-receptor positive breast cancer, diagnosed after the disease has spread, will be eligible for palbociclib, while those who meet the criteria and have gone through the menopause will be eligible for ribociclib.
“It's a life-changing drug for thousands of women and in years to come as well,” journalist Vikki Orvice, who was prescribed palbociclib for a two-year trial, told the BBC Radio 4's Today programme. “You get slight fatigue from it, but it was manageable and I was on the highest dose possible.
“No one looking at me would have known I was ill,” she added. “You have a quality of life with so few side effects.”
Baroness Delyth Morgan, chief executive of Breast Cancer Now, told The Guardian: “Around 8,000 women each year can now be given significant extra time before their condition progresses – time that will be truly invaluable to them and their loved ones.”
-
The IDF's manpower problemThe Explainer Israeli military's shortage of up to 12,000 troops results in call-up for tens of thousands of reservists
-
Quiz of The Week: 16 – 22 AugustQuiz Have you been paying attention to The Week's news?
-
Can Soho House get its edge back?Talking Point The private members' club has lost its exclusive appeal – but a £2 billion buy-out could offer a fresh start
-
How the care industry came to rely on migrant workersThe Explainer Government crackdown on recruiting workers abroad risks deepening care sector crisis, industry leaders warn
-
Could medics' misgivings spell the end of the assisted dying bill?Today's Big Question The Royal College of Psychiatrists has identified 'serious concerns' with the landmark bill – and MPs are taking notice
-
Washwood Heath: Birmingham's pioneering neighbourhood health serviceIn the Spotlight NHS England chair says there is a 'really good argument this is the model for the future'
-
The UK's first legal drug consumption roomThe Explainer 'Potentially transformative moment in UK drugs policy' as The Thistle opens in Glasgow
-
How can the UK solve the adult social care crisis?Today's Big Question New commission announced to turn our buckling care sector around: yet more delay or finally a way forward?
-
Should blood donors be paid?The Explainer Financial rewards would help fill NHS shortfall but bring risk of contamination and exploitation, WHO warns
-
UK gynaecological care crisis: why thousands of women are left in painThe Explainer Waiting times have tripled over the past decade thanks to lack of prioritisation or funding for women's health
-
The dark side of the contraceptive coilUnder the Radar Study linking hormonal IUD to increased breast cancer risk adds to growing concerns about whether the benefits of the coil outweigh the risks
